Suggested remit: To appraise the clinical and cost effectiveness of pertuzumab within its marketing authorisation for the adjuvant treatment of human epidermal growth factor receptor 2 (HER2) positive breast cancer.
Status In progress
Process STA pre-2018
ID number 1192

Provisional Schedule

Expected publication 24 October 2018

Project Team

Project lead Thomas Feist

Email enquiries


Key events during the development of the guidance:

Date Update
15 June 2018 - 06 July 2018 Appraisal consultation: 1
22 May 2018 Committee meeting: 1
01 December 2017 Invitation to participate
21 June 2017 - 18 July 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
22 July 2016 Referral
22 July 2016 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance